The effectiveness of anti-TNF- therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis
Open Access
- 21 June 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 49 (12), 2313-2321
- https://doi.org/10.1093/rheumatology/keq169
Abstract
Objectives. To systematically review and meta-analyse evidence on the effectiveness of the TNF-α inhibitors when used sequentially. Methods. Systematic review of comparative and single-arm observational studies. Data were synthesized using random-effects meta-analysis. Treatment effects were estimated using four outcome measures from the included studies: European League Against Rheumatism (EULAR) and ACR20 response rates and mean improvement in disease activity score-28 (DAS-20) and HAQ. The effect of other factors was explored via meta-regression and sub-group analyses. Results. Twenty studies comprising 2705 patients were included in the analysis. All studies were observational and most had no control group. Therefore, our primary analysis considered patient changes from baseline. The mean percentage of ACR20 responders was 60.8% (95% CI 53.8, 67.4), EULAR responders 70.5% (95% CI 63.7, 76.6), mean overall improvement in DAS-28 scores was 1.53 (95% CI 1.25, 1.80) and in HAQ scores was 0.25 (95% CI 0.11, 0.40). Four studies made comparisons with patients who received TNF-α inhibitors for the first time. Response rates associated with sequential TNF-α inhibitor treatment were lower than for first-time use. Conclusions. Sequential TNF-α inhibitor use is likely to lead to treatment benefit in terms of the signs and symptoms of disease and physical function. There is also some evidence to suggest that the probability of achieving a response is lower, and the average magnitude of response is lower than the first use. Further evidence from randomized controlled trials is required to confirm and further quantify the role specific anti-TNF-α agents have when used sequentially.Keywords
This publication has 36 references indexed in Scilit:
- Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposureRheumatology, 2005
- C‐reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: Defining subtypes of nonresponse and subsequent response to etanerceptArthritis & Rheumatism, 2005
- Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept.2004
- Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trialArthritis & Rheumatism, 2004
- Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trialArthritis & Rheumatism, 2004
- Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialThe Lancet, 2004
- Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor blockers can make senseAnnals Of The Rheumatic Diseases, 2003
- The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new centuryRheumatology, 2002
- The costs of rheumatoid arthritis: an international long-term viewSeminars in Arthritis and Rheumatism, 2000
- THE INCIDENCE OF RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM: RESULTS FROM THE NORFOLK ARTHRITIS REGISTERRheumatology, 1994